vivaCT80 - in vivo small animal microCT

描述(由申请人提供)：此申请是为了取代现有的microCAT，它已经支持了多个NIH资助的项目，但正在失败，无法修复。替代系统将支持所有当前的项目，并具有更高的分辨率、更快的扫描时间和更低的辐射剂量，这将使新的应用程序成为可能，从而将用途扩大到更多的研究项目。体内微型计算机断层成像系统用于对合成的、体外的标本进行非破坏性的三维分析，最重要的是，对活体动物进行分析。我们现有的microCAT II上的四个象限中有两个出现故障，无法修复，因为该仪器的制造商不再支持部件更换。建议的vivaCT80系统是目前可用的第一个也是唯一一个在体MicroCT系统，它可以产生分辨率足以分析小鼠骨小梁和微血管的图像，辐射剂量低，并且具有足够大的孔径，足以容纳小到灵长类动物。目前许多用户依赖活体MicroCT与PET、MRI和光学CT(FMT、Visen)进行联合配准和衰减计算。因此，体内microCT成像能力的丧失将影响到广泛生物医学领域的多个成像平台和项目。因此，vivCT80将为现有用户提供多年的稳定支持，并扩大NIH资助的众多广泛项目以及新用户和项目的试点项目。支持的项目研究血管生成、乳腺癌、前列腺癌和多发性骨髓瘤的骨骼后果、骨质量、软骨内骨化、阿尔茨海默病、药物开发、急性传染病和一系列软组织肿瘤等。这些项目的每一个方面都需要或将通过可靠、快速的活体显微CT成像得到显著增强。由于其改进的能力，vivaCT80无疑将促进范德比尔特大学内部和邻近机构的合作。将这台仪器安置在范德比尔特大学成像科学研究所(VUIIS)，该研究所在管理多种成像方式方面取得了巨大成功，将确保校园范围内的访问和卓越的管理。获得一种新的活体微型CT对于范德比尔特许多由NIH资助的赠款的持续成功绝对至关重要。

DESCRIPTION (provided by applicant): This application is to replace an existing microCAT that already supports multiple NIH-funded projects but is failing and cannot be repaired. The replacement system will support all of the current projects and have higher resolution, faster scan time, and lower radiation dose that will enable new applications, expanding usage to additional research projects. In vivo micro computed tomography systems are used for non-destructive three dimensional analyses of synthetic, ex vivo specimens, and, most importantly, live animals. Two of the four quadrants on our existing microCAT II have failed and cannot be repaired because the manufacturer of that instrument no longer supports parts replacement. The proposed vivaCT80 system is the first and only in vivo microCT system currently available that can produce images at a resolution sufficient for analysis of murine trabecular bone and microvasculature, low radiation dose, and possesses a bore size large enough to accommodate animals as large as small primates. Many current users depend on in vivo microCT for coregistration and attenuation calculations with PET, MRI, and optical CT (FMT, Visen). Hence, the loss of in vivo microCT imaging capabilities will affect multiple imaging platforms and projects across a wide range of biomedical fields. Thus, the vivCT80 will provide years of stable support for existing users and expand numerous, wide ranging, NIH funded projects as well as pilot projects for new users and projects. Supported projects study angiogenesis, skeletal consequences of breast and prostate cancer and multiple myeloma, bone quality, endochondral ossification, Alzheimer's disease, drug development, acute infectious disease, and a range of soft tissue tumors, among others. Aspects of each of these projects either require or will be substantially enhanced by reliable, fast, in vivo microCT imaging. Due to its improved capabilities, the vivaCT80 will undoubtedly foster collaborations within Vanderbilt University and at neighboring institutions. Housing this instrument in the Vanderbilt University Institute for Imaging Science (VUIIS), which has been highly successful in managing numerous imaging modalities, will ensure campus wide access and superior management. Acquisition of a new in vivo microCT is absolutely critical to the continued success of many NIH- funded grants at Vanderbilt.